DBV Technologies S.A. (NASDAQ:DBVT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Friday, September 8th.
According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “
DBVT has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of DBV Technologies in a report on Thursday, July 6th. BidaskClub lowered DBV Technologies from a “sell” rating to a “strong sell” rating in a report on Wednesday, June 14th. Deutsche Bank AG assumed coverage on DBV Technologies in a report on Friday, June 23rd. They set a “buy” rating and a $46.00 price target on the stock. Jefferies Group LLC reaffirmed a “buy” rating and issued a $47.00 price objective on shares of DBV Technologies in a research report on Thursday, June 1st. Finally, ValuEngine raised DBV Technologies from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. Two investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. DBV Technologies currently has a consensus rating of “Buy” and a consensus price target of $50.50.
Shares of DBV Technologies (NASDAQ DBVT) opened at 43.26 on Friday. DBV Technologies has a one year low of $31.87 and a one year high of $46.33. The company’s 50 day moving average is $44.12 and its 200 day moving average is $37.74. The company’s market capitalization is $1.99 billion.
COPYRIGHT VIOLATION WARNING: “DBV Technologies S.A. (DBVT) Cut to “Hold” at Zacks Investment Research” was originally posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://ledgergazette.com/2017/09/17/dbv-technologies-s-a-dbvt-rating-lowered-to-hold-at-zacks-investment-research.html.
Institutional investors have recently added to or reduced their stakes in the business. Point72 Asset Management L.P. purchased a new stake in DBV Technologies in the first quarter valued at about $1,120,000. Bank of America Corp DE raised its stake in DBV Technologies by 86.3% in the first quarter. Bank of America Corp DE now owns 26,574 shares of the company’s stock valued at $936,000 after buying an additional 12,309 shares during the last quarter. Morgan Stanley raised its stake in DBV Technologies by 89.9% in the first quarter. Morgan Stanley now owns 249,988 shares of the company’s stock valued at $8,805,000 after buying an additional 118,317 shares during the last quarter. Emory University raised its stake in DBV Technologies by 7.9% in the first quarter. Emory University now owns 62,884 shares of the company’s stock valued at $2,215,000 after buying an additional 4,628 shares during the last quarter. Finally, Jane Street Group LLC purchased a new stake in DBV Technologies in the first quarter valued at about $853,000. Institutional investors own 45.52% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.